Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays

Human Pathology

Volumn 40, Issue 9, 2009, Pages 1244-1251

  Cheng, Hongwei ^a   Dodge, Jim ^a   Mehl, Erika ^a   Liu, Shuzhen ^a   Poulin, Neal ^a   van de Rijn, Matt ^b   Nielsen, Torsten O ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IGF; Liposarcoma; RET; Tissue microarray

Indexed keywords

BIOLOGICAL MARKER; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR;

ADIPOGENESIS; ADULT; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CORRELATION ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MYXOSARCOMA; ONCOGENE RET; PROGNOSIS; PROTEIN DETERMINATION; SCORING SYSTEM; TISSUE MICROARRAY;

ADIPOGENESIS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; KAPLAN-MEIERS ESTIMATE; LIPOSARCOMA, MYXOID; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-RET; RECEPTOR, IGF TYPE 1; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SOFT TISSUE NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 68349160285     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2009.01.011     Document Type: Article

References (35)

1. Kransdorf M.J. Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. Am J Roentgenol 164 (1995) 129-134
2. Orvieto E., Furlanetto A., Laurino L., and Del Tos A.P. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol 18 (2001) 267-273
3. ten Heuvel S.E., Hoekstra H.J., van Ginkel R.J., Bastiaannet E., and Suurmeijer A.J. Clinicopathologic prognostic factors in myxoid liposarcoma: a retrospective study of 49 patients with long-term follow-up. Ann Surg Oncol 14 (2007) 222-229
4. Huang H.Y., and Antonescu C.R. Molecular variability of TLS-CHOP structure shows no significant impact on the level of adipogenesis: a comparative ultrastructural and RT-PCR analysis of 14 cases of myxoid/round cell liposarcomas. Ultrastruct Pathol 27 (2003) 217-226
5. Antonescu C.R. The role of genetic testing in soft tissue sarcoma. Histopathology 48 (2006) 13-21
6. Oikawa K., Ishida T., Imamura T., et al. Generation of the novel monoclonal antibody against TLS/EWS-CHOP chimeric oncoproteins that is applicable to one of the most sensitive assays for myxoid and round cell liposarcomas. Am J Surg Pathol 30 (2006) 351-356
7. Antonescu C.R., Tschernyavsky S.J., Decuseara R., et al. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res 7 (2001) 3977-3987
8. Riggi N., Cironi L., Provero P., et al. Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma. Cancer Res 66 (2006) 7016-7023
9. Kuroda M., Ishida T., Takanashi M., Satoh M., Machinami R., and Watanabe T. Oncogenic transformation and inhibition of adipocytic conversion of preadipocytes by TLS/FUS-CHOP type II chimeric protein. Am J Pathol 151 (1997) 735-744
10. Perez-Losada J., Sanchez-Martin M., Rodriguez-Garcia M.A., et al. Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma. Oncogene 19 (2000) 6015-6022
11. Adelmant G., Gilbert J.D., and Freytag S.O. Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function. J Biol Chem 273 (1998) 15574-15581
12. Barone M.V., Crozat A., Tabaee A., Philipson L., and Ron D. CHOP (GADD153) and its oncogenic variant, TLS-CHOP, have opposing effects on the induction of G1/S arrest. Genes Dev 8 (1994) 453-464
13. Nielsen T.O., West R.B., Linn S.C., et al. Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359 (2002) 1301-1307
14. Matushansky I., Hernando E., Socci N.D., et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 172 (2008) 1069-1080
15. Baird K., Davis S., Antonescu C.R., et al. Gene expression profiling of human sarcomas: insights into sarcoma biology. Cancer Res 65 (2005) 9226-9235
16. Henderson S.R., Guiliano D., Presneau N., et al. A molecular map of mesenchymal tumors. Genome Biol 6 (2005) R76
17. Nakayama R., Nemoto T., Takahashi H., et al. Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20 (2007) 749-759
18. Coindre J.M. Grading of soft tissue sarcomas: review and update. Arch Pathol Lab Med 130 (2006) 1448-1453
19. Nielsen T.O., Hsu F.D., O'Connell J.X., et al. Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. Am J Pathol 163 (2003) 1449-1456
20. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat (1979) 65-70
21. Fajas L., Fruchart J.C., and Auwerx J. Transcriptional control of adipogenesis. Curr Opin Cell Biol 10 (1998) 165-173
22. Kim K.A., Kim J.H., Wang Y., and Sul H.S. Pref-1 (preadipocyte factor 1) activates the MEK/extracellular signal-regulated kinase pathway to inhibit adipocyte differentiation. Mol Cell Biol 27 (2007) 2294-2308
23. Wiper-Bergeron N., Salem H.A., Tomlinson J.J., Wu D., and Hache R.J. Glucocorticoid-stimulated preadipocyte differentiation is mediated through acetylation of C/EBPbeta by GCN5. Proc Natl Acad Sci USA 104 (2007) 2703-2708
24. Quinkler M., and Stewart P.M. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 88 (2003) 2384-2392
25. Mazid M.A., Chowdhury A.A., Nagao K., et al. Endogenous 15-deoxy-Delta(12,14)-prostaglandin J(2) synthesized by adipocytes during maturation phase contributes to upregulation of fat storage. FEBS Lett 580 (2006) 6885-6890
26. Shao D., and Lazar M.A. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 272 (1997) 21473-21478
27. Grimaldi P.A. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell Mol Life Sci 64 (2007) 2459-2464
28. Wang Y., Kim K.A., Kim J.H., and Sul H.S. Pref-1, a preadipocyte secreted factor that inhibits adipogenesis. J Nutr 136 (2006) 2953-2956
29. Hauner H., Entenmann G., Wabitsch M., et al. Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 84 (1989) 1663-1670
30. Gregoire F., Genart C., Hauser N., and Remacle C. Glucocorticoids induce a drastic inhibition of proliferation and stimulate differentiation of adult rat fat cell precursors. Exp Cell Res 196 (1991) 270-278
31. Draper N., and Stewart P.M. 11beta-Hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol 186 (2005) 251-271
32. Arighi E., Borrello M.G., and Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 16 (2005) 441-467
33. Tao Y., Pinzi V., Bourhis J., and Deutsch E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol 4 (2007) 591-602
34. Wan X., and Helman L.J. The biology behind mTOR inhibition in sarcoma. Oncologist 12 (2007) 1007-1018
35. Plaza-Menacho I., Mologni L., Sala E., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem 282 (2007) 29230-29240